The Tissue Bank and Biomarkers Core (TBBC) is the central repository of specimens necessary for the execution of the studies of the Colorado SPORE In Lung Cancer program. Furthermore, as an extensive resource for lung cancer related specimens, the TBBC also provides specimens to extramural investigators when there are adequate materials to accommodate these requests beyond the needs of the internal projects. The three primary goals of the TBBC are to procure, characterize and process, and distribute specimens. The provision of these services takes advantage of a close working relationship with the existing facilities, infrastructure, and personnel for biobanking and histology operations of the University of Colorado Cancer Center Tissue Biobanking and Processing Shared Resource. Two general banks are maintained: a tumor bank and a premalignant bank. Specimens for both of these banks are collected as archival tissue or, in collaboration with the Clinical Trials Core, SPORE trial associated specimens and are obtained under IRB approved protocols. In addition to tissue, ancillary specimens including blood, sputa, urine and special bronchoscopic specimens are collected. The TBBC, in collaboration with the Biostatistics and Bioinformatics core of the SPORE, also collects correlative clinical and biologic information that can be included in specimen distributions. The TBBC provides histologic and cytologic interpretation, prepares RNA, DNA and protein samples, creates TMAs and provides molecular analysis on selected specimens required by the SPORE projects. This includes histologic review and classification by up-to-date published WHO classification systems for malignant and pre-malignant lesions of the lung by the pathologist members of the core. The core designs its activities to meet the needs of each of the SPORE projects as outlined In the proposal. In order to meet the tissue needs and achieve the goals of the projects, the TBBC collects and processes tissues in a specific manner as determined via collaboration with project investigators. The TBBC also collaborates in the performance of project related studies in which expertise of TBBC personnel can benefit study design, data generation, and data analysis.

Public Health Relevance

The Tissue Biobanking and Biomarkers Core (TBBC) is essential to the success of the Colorado SPORE In Lung Cancer program. The TBBC is a central service that obtains tissues and information from patients with lung cancer or at high-risk for lung cancer. The collected tissue and Information is stored and processed so that researchers have the best possible materials and Information for their projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-19A1
Application #
8664640
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-04-30
Support Year
19
Fiscal Year
2014
Total Cost
$261,244
Indirect Cost
$89,634
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Symonds, Jennifer M; Ohm, Angela M; Tan, Aik-Choon et al. (2016) PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget 7:17905-19
Dziadziuszko, Rafal; Le, Anh T; Wrona, Anna et al. (2016) An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol 11:1273-81
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Scarborough, Hannah A; Helfrich, Barbara A; Casas-Selves, Matias et al. (2016) AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin Cancer Res :
Poczobutt, Joanna M; Nguyen, Teresa T; Hanson, Dwight et al. (2016) Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol 196:891-901
Li, Bob T; Ross, Dara S; Aisner, Dara L et al. (2016) HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol 11:414-9
Yoshida, Takeshi; Song, Lanxi; Bai, Yun et al. (2016) ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One 11:e0147344
Ariyawutyakorn, Witthawat; Saichaemchan, Siriwimon; Varella-Garcia, Marileila (2016) Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 7:633-49
Bunn Jr, Paul A; Minna, John D; Augustyn, Alexander et al. (2016) Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 11:453-74
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322

Showing the most recent 10 out of 350 publications